Insulin resistance in muscle, liver and fat, then beta-cell strain, is explained before any drug in NU559's Unit 6 brief; glucose-lowering classes follow, each assigned to its tissue. Searches like "nu 559 unit 6 assignment example", "nu559 unit 6 sample" and "nu559 unit 6 example" land here.
Resistance First, Drugs Second: An Endocrine Mechanism Brief for New Type 2 Diabetes With Acanthosis Nigricans
[Student Name]
Purdue University Global
NU559: Essentials of Advanced Pathophysiology and Pharmacology
Unit 6 Endocrine Mechanism Brief
[Instructor Name]
[Date]
The patient is a composite; values and agents in brackets are illustrative.
1. Resistance, Tissue by Tissue
Mr. [S.], 49, supervises a call center and sits for most of his ten-hour shifts. His A1c of 6.9 percent, confirmed on a repeat test, meets the threshold for type 2 diabetes. DeFronzo (2009) described eight defects that contribute to hyperglycemia in type 2 diabetes; four explain this patient.
Muscle. After a meal, insulin normally signals muscle cells to move GLUT4 glucose transporters from inside the cell to its membrane, and muscle takes up most of the glucose from the meal. In insulin resistance, that signal is weakened, fewer transporters reach the membrane, and glucose stays in the blood longer after meals (Samuel & Shulman, 2016).
Liver. Overnight, the liver releases glucose to keep levels steady, and insulin normally restrains that output. A resistant liver keeps producing glucose despite high insulin levels, which is why his fasting glucose is raised.
Fat. Insulin normally suppresses the breakdown of stored fat. Resistant fat tissue releases more free fatty acids, which travel to muscle and liver and worsen resistance in both, a feedback loop.
Skin. Acanthosis nigricans, the velvety darkening at the back of his neck, is a sign of high circulating insulin. At high concentrations, insulin acts on insulin-like growth factor receptors in skin, stimulating keratinocytes and fibroblasts to proliferate.
2. The Beta Cell Falls Behind
For years, the beta cell compensates for resistance by making more insulin, and glucose stays normal; diabetes appears when the beta cell can no longer keep up. His acanthosis shows how hard his beta cells have been working. As beta-cell function declines, fasting and after-meal glucose rise. That decline continues, which is why many people need more than one agent over time.
3. Six Classes at Their Sites
1. [Metformin]. Site: liver. Mechanism: reduces hepatic glucose output, through a mechanism still debated. Glucose-dependent action: no, but it does not raise insulin, so low glucose is rare alone.
2. Thiazolidinedione, such as [pioglitazone]. Site: fat and muscle. Mechanism: activates PPAR-gamma, a nuclear receptor, increasing insulin sensitivity. Glucose-dependent: no, but it does not raise insulin; low glucose is rare alone.
3. GLP-1 receptor agonist, such as [semaglutide]. Site: beta cell, stomach and brain. Mechanism: raises insulin and lowers glucagon when glucose is high, slows gastric emptying, reduces appetite. Glucose-dependent: yes.
4. DPP-4 inhibitor, such as [sitagliptin]. Site: gut hormones. Mechanism: slows the breakdown of the body's own GLP-1. Glucose-dependent: yes.
5. SGLT2 inhibitor, such as [empagliflozin]. Site: kidney. Mechanism: blocks glucose reabsorption in the proximal tubule, so glucose is lost in urine. Glucose-dependent: largely, since less glucose is filtered at lower levels.
6. Sulfonylurea, such as [glipizide]. Site: beta cell. Mechanism: closes ATP-sensitive potassium channels, releasing insulin. Glucose-dependent: no.
4. Predicting Low Glucose From Mechanism
A drug that releases insulin regardless of the glucose level can drive glucose too low. Sulfonylureas close the beta cell's potassium channels whatever the glucose, so they are the likeliest of the six to cause lows when used alone. The two incretin-based classes raise insulin only when glucose is high, and their effect fades as glucose falls. Metformin and thiazolidinediones do not raise insulin at all. SGLT2 inhibitors lose effect as glucose falls because less glucose reaches the tubule.
The class a prescriber would likely weigh first for Mr. [S.] is [metformin], with a GLP-1 receptor agonist considered if weight loss or cardiovascular risk reduction is a priority, following current standards (American Diabetes Association Professional Practice Committee, 2025). His sedentary work and the acanthosis also point to the upstream step that no drug replaces: activity and weight reduction improve insulin sensitivity in muscle and liver directly.
References
American Diabetes Association Professional Practice Committee. (2025). Standards of care in diabetes 2025. Diabetes Care, 48(Suppl. 1), S1-S352. https://diabetesjournals.org/care
DeFronzo, R. A. (2009). From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 58(4), 773-795. https://doi.org/10.2337/db09-9028
Samuel, V. T., & Shulman, G. I. (2016). The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux. Journal of Clinical Investigation, 126(1), 12-22. https://doi.org/10.1172/JCI77812
How this NU559 Unit 6 example is structured
Mechanism precedes pharmacology in strict order, and that is the brief's defining choice. Nothing about drugs appears until the resistance and beta-cell story is complete, so each class arrives as an answer to a problem already stated. DeFronzo's ominous octet (2009) is cited as the framework and then trimmed to the four defects this patient shows, since eight organs at equal weight would bury the case. The drug section is a table with three columns: site, mechanism and whether the action depends on glucose. That third column carries the brief's clinical point. Metformin reduces hepatic glucose output through a mechanism still debated, a thiazolidinedione sensitizes fat and muscle through PPAR-gamma, GLP-1 receptor agonists raise insulin only when glucose is high, and sulfonylureas close potassium channels regardless of glucose, which makes them the likeliest of the six to cause lows alone.
Get an NU559 Unit 6 example written to your instructions
Endocrine briefs in NU559 are not always about diabetes; some sections use thyroid or adrenal disorders instead. Tell the desk which gland or disorder the Unit 6 prompt centers on and include the case with its grading rubric. Mechanism written before any drug and values bracketed throughout, the sample brief comes back in 24-48h, free the first time. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU559 Unit 6 questions, answered
Should the brief discuss insulin itself as a therapy?
Briefly, if the prompt allows. Insulin replaces what the failing beta cell no longer supplies, so it fits the mechanism story at its final stage. For a newly diagnosed patient with modest values, most briefs mention it as the endpoint of progression rather than the focus, keeping attention on the resistance mechanisms the unit was built around.
How long is an endocrine mechanism brief expected to be?
Briefs are usually shorter than papers, often two to four pages, and some sections set a word limit instead. That pressure is the point, since the format rewards choosing only the mechanisms that explain the case and its drugs. See whether references count toward the limit in your prompt, because that changes how much room the argument actually has.
Is it acceptable to say a mechanism is not fully understood?
Yes, and graders often credit it. The molecular target of metformin is still debated, and stating that plainly is more accurate than repeating a single pathway as settled. Name what is established, that hepatic glucose output falls, then note the uncertainty in one sentence with a source. Overclaiming certainty is a more common fault than admitting a gap.